Focusfreda Successfully Defends Against Patent Infringement Dispute, Upholds Legal Rights

On March 26, 2025, the Shanghai Intellectual Property Court ruled on two patent infringement disputes between the plaintiff, Shanghai Huiwen Biotechnology Co., Ltd. (hereinafter “Huiwen Biotechnology”), and the defendants, Shandong Focusfreda Biotechnology Co., Ltd. (hereinafter “Focusfreda”) and Huaiwei Industrial (Shanghai) Co., Ltd. The court approved the plaintiff’s withdrawal of the lawsuits, concluding the nearly two-year patent dispute in favor of Focusfreda.

Case Review

May 2023: Huiwen Biotechnology filed its first lawsuit (Case No. 21) with the Shanghai Intellectual Property Court, alleging that Focusfreda infringed its Invention Patent No. 200510029745.1 (hereinafter “Patent 745”). It demanded Focusfreda cease the alleged infringement and compensate RMB 20 million for economic losses and legal fees.
August 2023: Huiwen Biotechnology filed a second lawsuit (Case No. 48), claiming Focusfreda infringed its Invention Patent No. 200510023427.4 (hereinafter “Patent 427”) and sought RMB 80 million in compensation.
January 19, 2024: Case No. 21 was officially accepted by the court.
February 22, 2024: Case No. 48 was officially accepted.
March 2024: Focusfreda engaged legal counsel from AllBright Law Offices. After thorough analysis, the team concluded the allegations lacked factual basis and filed an invalidation request against Patent 745.
April 2024: Focusfreda temporarily withdrew the invalidation request for Patent 745 to refine its legal strategy and evidence.
August 30, 2024: Focusfreda re-filed invalidation requests for both Patent 745 and Patent 427 with strengthened evidence.
March 7, 2025: Both patents were declared fully invalid, stripping Huiwen Biotechnology of its legal standing to continue the lawsuits.
March 26, 2025: The court approved Huiwen Biotechnology’s withdrawal, with litigation costs borne by the plaintiff.

Intellectual Property Compliance and Protection
As a national high-tech enterprise, national manufacturing “single champion” demonstrator, and national specialized “little giant” enterprise, Focusfreda strictly adheres to China’s Patent Law and Anti-Unfair Competition Law. Innovation and R&D form the core of its strategy, supported by proactive patent filings, dedicated IP protection budgets, and compliance integration across R&D, production, and sales. This commitment ensures reliable technological safeguards for clients and sets a benchmark for industry integrity.

Corporate Stance and Vision
Facing combined claims of RMB 100 million, Focusfreda upheld the rule of law, defended its rights with facts and legal rigor, and ultimately prevailed. This victory not only validates Focusfreda’s legitimacy but also highlights its resolve in IP protection and its responsibility as a state-owned enterprise to operate lawfully. It serves as an inspiration for all IP-respecting, compliance-driven businesses.

Moving forward, Focusfreda will intensify R&D and IP protection investments to enhance core competitiveness and ensure lawful innovation commercialization. Driven by innovation and grounded in compliance, it will advance steadily to deliver greater value to clients and foster industry progress.

Focusfreda also pledges to collaborate with industry peers in building a fair, healthy market environment to propel sustainable development.

山东焦点福瑞达生物股份有限公司